Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
News: Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors

Sermonix Pharmaceuticals Completes Enrollment of Phase 2 Clinical Trial Collaboration Studying Lasofoxifene in Combination With Eli Lilly and Company's Abemaciclib

06/28/2021 | 10:14am EDT

COLUMBUS, Ohio, June 28, 2021 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to treat ESR1-mutated metastatic breast and gynecological cancers, today announced that enrollment has been completed for its Phase 2 clinical trial collaboration of its lead investigational drug, lasofoxifene, in combination with Eli Lilly and Company’s FDA-approved CDK 4 and 6 inhibitor, abemaciclib. Sermonix expects initial data from the trial to be available in the first half of 2022.

“Combination therapy in the metastatic setting is becoming quite commonplace and the potential to pair a well-tolerated endocrine therapy with a CDK 4/6 inhibitor in women with an ESR1 mutation is important from a clinical perspective, thus it is vital to assess safety and tolerability of these agents used concomitantly to optimize progression-free survival,” said Dr. David Portman, Sermonix founder and chief executive officer. “We are delighted to have promptly completed enrollment and thank our participants, their families and clinical centers for supporting our efforts.”

The open-label, multi-center study is evaluating the safety of lasofoxifene in combination with abemaciclib for the treatment of pre- and postmenopausal women with locally advanced metastatic estrogen receptor-positive (ER+)/HER2- breast cancer and an ESR1 mutation. It is Sermonix’s second Evaluation of Lasofoxifene in ESR1 Mutations (ELAINE) study and is known as ELAINE 2.

Sermonix partnered with Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, to assist in identifying and enrolling patients in the ELAINE 2 study. Leveraging Tempus’ AI capabilities and the TIME Trial® program, Sermonix was able to find patients in real-time, especially eligible ESR1+ patients who are treated in the community setting.

Preclinical models of invasive breast cancer at the University of Chicago – recently published in the journal Breast Cancer Research – identified synergy between lasofoxifene, a selective estrogen receptor modulator (SERM), and a CDK 4 and 6 inhibitor in the presence of ESR1 mutations.

“The completion of ELAINE 2 enrollment marks an important preparative step toward conducting a larger efficacy study of lasofoxifene in combination with a CDK 4/6 inhibitor,” said Dr. Paul Plourde, Sermonix vice president of clinical development. “We are delighted with the fast study enrollment – particularly given the challenges of the pandemic – and the momentum of lasofoxifene and our ELAINE program as we look to share initial data early in 2022.”

For more information about the ELAINE studies, visit https://www.elainestudy.com.

About Lasofoxifene
Lasofoxifene is an investigational, nonsteroidal selective estrogen receptor modulator (SERM), which Sermonix licensed globally from Ligand Pharmaceuticals Inc. (NASDAQ: LGND) and has been studied in previous comprehensive Phase 1-3 non-oncology clinical trials in more than 15,000 postmenopausal women worldwide. Lasofoxifene’s bioavailability and activity in mutations of the estrogen receptor could potentially hold promise for patients who have acquired endocrine resistance due to ESR1 mutations, a common finding in the metastatic setting and an area of high unmet medical need. Lasofoxifene’s novel activity in ESR1 mutations was discovered at Duke University and Sermonix has exclusive rights to develop and commercialize the product in this area. Lasofoxifene, a potent, oral SERM could, if approved, play a critical role in the targeted precision medicine treatment of advanced ER+ breast cancer.

About Abemaciclib
Abemaciclib (trade name Verzenio®) is a CDK4 and 6 inhibitor and the first and only oral tablet of its kind that can be taken every day for the treatment of HR+, HER2– metastatic breast cancer. It is indicated for the treatment of HR+, HER2- advanced or metastatic breast cancer, in combination with an aromatase inhibitor for postmenopausal women as initial endocrine-based therapy; in combination with fulvestrant for women with disease progression following endocrine therapy; or as a single agent for adult patients with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.

About Sermonix
Sermonix Pharmaceuticals Inc. is a privately held biopharmaceutical company focused on the development of female-specific oncology products and is currently undertaking two Phase 2 clinical studies of lasofoxifene, its lead investigational drug. Sermonix Pharmaceuticals was founded in 2014 by David Portman, M.D., a leading clinical researcher and expert in women’s health, menopause and selective estrogen receptor modulator (SERM) therapy. The Sermonix management team, led by Dr. Portman, has significant experience in all stages of the drug development and regulatory process. Paul Plourde, M.D., vice president of oncology clinical development, has many decades of experience in the oncology drug development arena. Barry Komm, Ph.D., chief scientific officer, is recognized for his expertise in SERM biology. Miriam Portman, M.D., is chief operating officer. Elizabeth Attias, M.M.Sc., Sc.D., chief strategy and development officer, has extensive experience in pharmaceutical drug commercialization. Simon Jenkins, Ph.D. vice president of operations, has over 30 years of experience in global drug development leadership. Sermonix non-executive chairman of the board is Anthony Wild, Ph.D., former president of both Parke-Davis Pharmaceuticals and Warner-Lambert’s Pharmaceutical Division. Learn more at https://sermonixpharma.com/.

Contact information:
Glenn Garmont
LifeSci Advisors
Managing Director, Investor Relations Corporate Communications
ggarmont@lifesciadvisors.com
646-876-5521


Primary Logo


ę GlobeNewswire 2021
Latest news "Companies"
07:38aSOLV WELLNESS : ™, Makers of Ellura«, Launches new Female Pelvic Health Prebiotic Māge with a Proprietary Blend of the Most Clinically Studied Pre- and Probiotics
PR
07:38aVeteran Product and Engineering Leaders From Workday and Salesforce Join Tendo to Build Transformational Healthcare Software
BU
07:36aSTATERA BIOPHARMA : to Participate in the Benzinga Healthcare Small Cap Conference
PR
07:36aFREQUENCY THERAPEUTICS, INC. : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
07:36aDOCGO : Increases Mobile Health Offerings for Individuals with Disabilities on Long Island
PR
07:36aFinEx Funds ICAV - Net Asset Value
PR
07:35aBritain tells its food industry to prepare for CO2 price shock
RE
07:35aIMEDIA BRANDS, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
07:35aMATCH GROUP, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
07:35aAdvance United Holdings (AUHI) Initiates 2021 Work Program on Buck Lake Property
NE
Latest news "Companies"